REED ELIZABETH E 4
4 · Travere Therapeutics, Inc. · Filed Feb 12, 2025
Insider Transaction Report
Form 4
REED ELIZABETH E
Chief Legal Officer and GC
Transactions
- Exercise/Conversion
Common Stock
2025-02-10+8,000→ 97,482 total - Exercise/Conversion
Performance-based restricted stock units
2025-02-10−8,000→ 0 total→ Common Stock (8,000 underlying) - Sale
Common Stock
2025-02-12$23.53/sh−8,000$188,240→ 89,482 total
Footnotes (3)
- [F1]On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.
- [F2]Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
- [F3]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of the PSUs.